Nasal polyps are soft, painless growths on the lining of your nasal passages or sinuses, often resulting from chronic inflammation. While these benign growths themselves are not harmful ...

Amgen (AMGN) and AstraZeneca's (AZN) asthma therapy Tezspire hits main goals in the Phase 3 trial for chronic rhinosinusitis ...

Topline results from a phase 3 trial show that tezepelumab statistically significantly reduced the size of nasal polyps and nasal congestion in adults with chronic rhinosinusitis with nasal polyps ...

Nasal polyps are small noncancerous growths in the nose or sinuses. They may cause pain or pressure in the face, runny or stuffy nose, and other symptoms or complications that may negatively ...

Both trials met their co-primary endpoints of a change from baseline in total endoscopic nasal polyp score at 52 weeks and a change from baseline in mean nasal obstruction score from weeks 49 to 52.

The study's co-primary endpoints were to see the change from baseline in total endoscopic nasal polyp score at 52 weeks and the change from baseline in mean nasal obstruction score from weeks 49 ...

A Phase III trial with the companies’ monoclonal antibody in patients with chronic rhinosinusitis with nasal polyps met its ...

GSK’s blockbuster hopes for depemokimab remain on track after the investigational long-acting asthma treatment has also been shown to reduce nasal polyps in a pair of phase 3 trials. The ANCHOR ...

AstraZeneca has failed in its bid to get US approval for its IL-5 inhibitor Fasenra as a treatment for chronic rhinosinusitis in people with nasal polyps, after the FDA rejected its marketing ...

Dr. Albritton is a resident physician and Dr. Kingdom is Assistant Professor in the Department of Otolaryngology at Emory University School of Medicine, Atlanta, Ga. Albritton FD, Kingdom TT.